MX8403A - Procedimiento para la preparacion de (4-trifluro metil)-anilida de acido 5 metil-isoxasol-4-carboxilico. - Google Patents

Procedimiento para la preparacion de (4-trifluro metil)-anilida de acido 5 metil-isoxasol-4-carboxilico.

Info

Publication number
MX8403A
MX8403A MX8403A MX840384A MX8403A MX 8403 A MX8403 A MX 8403A MX 8403 A MX8403 A MX 8403A MX 840384 A MX840384 A MX 840384A MX 8403 A MX8403 A MX 8403A
Authority
MX
Mexico
Prior art keywords
methyl
isoxasol
procedure
preparation
anilide
Prior art date
Application number
MX8403A
Other languages
English (en)
Inventor
Friedrich-Johannes Kammerer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX8403A publication Critical patent/MX8403A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

la presente se relaciona con un procedimiemto para la preparacion de (4-trifluorometil) - anilida de ácido 5-metil-isoxasol-4-carboxilico que cunsiste en hacer reaccinar la 4-trifluorometilanilina con diceteno o un derivado reactivo de ácido acepto-acético; calentar la 4-trifluoro- metilanilida de ácido eceto-acético asi obtenida, con un éter de ácido ortofórmico de la formula hc(or)3, en donde R representa un alquilo de 1 a 4 atomos de carbono y con un anhídrido ácido; y hacer reaccionar la 4- trifluorometilanilida de ácido 2-alcoximetilenacetoacético asi obtenida con hidroxilaminas.
MX8403A 1978-12-16 1984-03-12 Procedimiento para la preparacion de (4-trifluro metil)-anilida de acido 5 metil-isoxasol-4-carboxilico. MX8403A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (1)

Publication Number Publication Date
MX8403A true MX8403A (es) 1994-03-31

Family

ID=6057414

Family Applications (2)

Application Number Title Priority Date Filing Date
MX798546U MX6174E (es) 1978-12-16 1979-12-13 Procedimiento para la preparacion de(4-trifluorometil)-anilida de acido 5-metil-isoxazol-4-carboxilico
MX8403A MX8403A (es) 1978-12-16 1984-03-12 Procedimiento para la preparacion de (4-trifluro metil)-anilida de acido 5 metil-isoxasol-4-carboxilico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX798546U MX6174E (es) 1978-12-16 1979-12-13 Procedimiento para la preparacion de(4-trifluorometil)-anilida de acido 5-metil-isoxazol-4-carboxilico

Country Status (25)

Country Link
US (2) US4284786A (es)
EP (1) EP0013376B1 (es)
JP (1) JPS5583767A (es)
AR (2) AR222680A1 (es)
AT (1) ATE1067T1 (es)
AU (1) AU529341B2 (es)
BG (1) BG60764B2 (es)
CA (1) CA1129867A (es)
DE (2) DE2854439A1 (es)
DK (1) DK149886C (es)
EG (1) EG13926A (es)
ES (2) ES486750A1 (es)
FI (1) FI64154C (es)
GR (1) GR72731B (es)
HU (1) HU178015B (es)
IE (1) IE49126B1 (es)
IL (1) IL58951A (es)
LU (1) LU90466I2 (es)
MX (2) MX6174E (es)
NL (1) NL990037I1 (es)
NO (1) NO148925C (es)
NZ (1) NZ192400A (es)
PH (1) PH16627A (es)
PT (1) PT70596A (es)
ZA (1) ZA796793B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
DE59407413D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DK0607774T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 1 alfa
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
TW314467B (es) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
CA2202904C (en) * 1994-10-17 2006-12-19 Yukio Amano Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ES2150808T3 (es) * 1997-08-08 2000-12-01 Aventis Pharma Gmbh Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20030139606A1 (en) * 2001-11-09 2003-07-24 Ray Anup Kumar Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
EP1920772A4 (en) * 2005-08-31 2010-11-17 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR COMBATING RHEUMATOID ARTHRITIS
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
MX2022010962A (es) 2020-03-06 2022-10-07 Actelion Pharmaceuticals Ltd Metodos para ralentizar la perdida de volumen cerebral.
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
EP4415699A1 (en) 2021-10-11 2024-08-21 Laboratoires Juvise Pharmaceuticals Methods of treating multiple sclerosis
US20240261268A1 (en) 2022-02-11 2024-08-08 Vanda Pharmaceuticals Inc. Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
GR72731B (es) 1983-12-01
JPH0133470B2 (es) 1989-07-13
AR226894A1 (es) 1982-08-31
PT70596A (de) 1980-01-01
LU90466I2 (fr) 2000-01-03
HU178015B (en) 1982-02-28
IL58951A0 (en) 1980-03-31
FI64154C (fi) 1983-10-10
FI64154B (fi) 1983-06-30
NO794094L (no) 1980-06-17
DE2854439A1 (de) 1980-07-03
MX6174E (es) 1984-12-04
ES486750A1 (es) 1980-06-16
EP0013376B1 (de) 1982-05-19
ES486758A1 (es) 1980-05-16
DE2962929D1 (en) 1982-07-08
EP0013376A2 (de) 1980-07-23
EG13926A (en) 1982-09-30
NO148925B (no) 1983-10-03
PH16627A (en) 1983-12-05
ATE1067T1 (de) 1982-06-15
EP0013376A3 (en) 1980-09-17
NZ192400A (en) 1982-02-23
DK149886B (da) 1986-10-20
DK534279A (da) 1980-06-17
AU5385379A (en) 1980-06-19
US4351841A (en) 1982-09-28
JPS5583767A (en) 1980-06-24
DK149886C (da) 1987-04-21
IL58951A (en) 1984-01-31
BG60764B2 (bg) 1996-02-29
NL990037I2 (nl) 2000-01-03
NL990037I1 (nl) 2000-01-03
NO148925C (no) 1984-01-11
ZA796793B (en) 1980-11-26
IE49126B1 (en) 1985-08-07
US4284786A (en) 1981-08-18
AU529341B2 (en) 1983-06-02
CA1129867A (en) 1982-08-17
FI793899A (fi) 1980-06-17
AR222680A1 (es) 1981-06-15
IE792426L (en) 1980-06-16

Similar Documents

Publication Publication Date Title
MX8403A (es) Procedimiento para la preparacion de (4-trifluro metil)-anilida de acido 5 metil-isoxasol-4-carboxilico.
IT7950404A0 (it) Composti di acido epossisuccinammi co dotati di proprieta' farmacologiche e procedimento di preparazione
ES8500917A1 (es) Procedimiento para la obtencion de azolilmetilcicloalcanos
MX6389E (es) Procedimiento para la preparacion de derivados de acido 17b-hidroxi-3-oxo-7alpha-alquilo,cicloalquilalquilo o arilalquilo-(17alpha)-pregn-4-en-21-carboxilico
ES481650A1 (es) Procedimiento de sintesis de esteroides utilizando un anhi- drido mixto.
JPS5657775A (en) Thiazole derivative
ES472511A1 (es) Procedimiento para la obtencion de derivados del acido 13 tianoprostanico
DK190484A (da) Fremgangsmaade til fremstilling af 3-hydroxy-5-methylisoxazol
JPS5490171A (en) 5-cyano-1-methylpyrrole-2-acetic acid and its preparation
JPS54148757A (en) (2-fluoro-4-biphenylyl) ketene mercaptal s-oxide
JPS5287129A (en) 4-trifluoromethyl phenoxy phenoxyankane carboxylic acid
JPS54148758A (en) Alpha-thio-alpha-(2-fluoro-4-biphenylyl)carboxylic acid derivative
JPS57106654A (en) Phenyl ether type compound and herbicide comprising it
ES471168A1 (es) Un procedimiento para la obtencion de 2-p-clorofenil-1,5,5- trimetil- 4-metilenpiperidina
JPS5581861A (en) Nicotinamide derivative
JPS5461156A (en) Tropolone derivative
JPS55736A (en) Hardening of gelatin
JPS56123959A (en) Fluoroazoxybenzene derivative
JPS55149223A (en) Preparation process of 4-allyl or methallyloxyphenyl- acetic acids
KR840001559A (ko) 이속사졸 유도체의 제조방법
ES483995A3 (es) Procedimiento para la preparacion de nuevos anhidridos de ester de n-fosfonometilglicina
JPS53111391A (en) Preparation of modified wax
ES8305332A1 (es) Procedimiento para la obtencion del 1-ciclohexanol- butirato de nicotinamida.
JPS5716849A (en) Alkyl o-gamma-monobromoacetoacetamidobenzoate and its preparation
JPS5368739A (en) Aminopropanol derivatives and their salts preparation